Las Vegas, NV -- (SBWIRE) -- 01/23/2014 -- EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more .EquityObserver.com issues a special report on the following stocks: J.C. Penney Company, Inc.(NYSE:JCP), Vringo, Inc.(NASDAQ:VRNG), Cell Therapeutics Inc(NASDAQ:CTIC), IAMGOLD Corp (USA)(NYSE:IAG)
J.C. Penney Company, Inc.(NYSE:JCP) was a volume gainer of 16.59 million shares and the average volume of the stock remained 27.23 million shares. The stock opened the session at $6.56 and finished at the end of the day at $6.75 and the stock escalated 4.01%.The market capitalization of the stock remained 2.06 billion. J. C. Penney Company, Inc., through its subsidiary, J. C. Penney Corporation, Inc., operates department stores. The company sells family apparel and footwear, accessories, fine and fashion jewelry, beauty products, and home furnishings.
For How Long JCP will fight for Profitability? Read This Trend Analysis report
In the preceding trading session, Vringo, Inc.(NASDAQ:VRNG) exchanged 16.59 million shares and the average volume remained 1.25 million shares. The stock closed the session at $3.81 with the gain of 21.73%. Vringo, Inc., together with its subsidiaries, engages in the innovation, acquisition, licensing, and protection of intellectual property worldwide. Its intellectual property portfolio consists of approximately 500 patents and patent applications covering telecom infrastructure, Internet search, and mobile technologies.
Will VRNG Continue To Move Higher? Find Out Here
Cell Therapeutics Inc(NASDAQ:CTIC) decreased -4.75% and its closing price was $4.01. The volume of the stock was 14.62 million shares and the average volume remained 5.15 million shares. The market capitalization of the stock remained 586.21 million. The beta of the stock remained 5.57. Cell Therapeutics, Inc. acquires, develops, and commercializes treatments for cancer. The company primary focuses on the commercialization of PIXUVRI, an aza-anthracenedione derivative, which is in Phase III clinical trials for the treatment of multiply relapsed or refractory aggressive non-Hodgkin lymphoma.
Will CTIC Get Buyers Even After The Recent Rally? Find Out Here
IAMGOLD Corp (USA)(NYSE:IAG) exchanged 14.22 million shares in the previous trading session, and its average trading remained 7.52 million shares. IAG dropped -11.95% and it closed the trading at $3.61. The market capitalization of the stock remained 1.36 billion. IAMGOLD Corporation engages in the exploration, development, and operation of mining properties. Its products include gold, silver, niobium, and copper deposits. The company holds interests in six gold mines, and a niobium mine, as well as exploration and development projects located in Africa and South America.
Has IAG Found The Bottom and Ready To Move Up? Find Out Here
About Equity Observer:
Equity Observer delivers intra-day insights into the equities, tech and investment world. The website is a window into what’s going on in the business world and why.
EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more.
The disclaimer is to be read and fully understood before using our site, or joining our email list.
http://www.equityobserver.com/ has a no tolerance spam policy; we will not sell or re-distribute your email to any 3rd party. A If applicable, please also unsubscribe from the newsletter using the link at the bottom of the email if you no longer wish to receive our emails. We only send our newsletters to opt-in members.
PLEASE NOTE WELL: The http://www.equityobserver.com/" rel="nofollow" href="http://www.equityobserver.com/">http://www.equityobserver.com/&l...; employees and contributors are NOT registered as an Investment Adviser in any jurisdiction whatsoever.
Read Full Disclaimerat: http://www.equityobserver.com/>
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)